Insmed reported $215.32M in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Cytokinetics USD 6.83M 10.94M Mar/2026
DBV Technologies USD 15.1M 1.05M Mar/2026
Gilead Sciences USD 5.06B 314M Jun/2026
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Insmed USD 215.32M 36.77M Jun/2026
Novartis USD 9.6B 2.69B Mar/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2.13B 138.2M Jun/2026